Company profile
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc.

Pipeline2 assets

  • cantharidinVP-102 / YCANTH / Unknown / Small Molecule / Dermatology
    Molluscum ContagiosumApprovedActiveCommon WartsPhase 3ActiveExternal Genital WartsPhase 2Active
  • VP-315VP-315 / Oncolytic peptide / Peptide / Dermatologic Oncology
    Basal Cell CarcinomaPhase 2ActiveSquamous Cell CarcinomaPhase 1/2Active

Latest news12 items

All news

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts – WEST

Trial Start • Phase 3Trial initiation Mon, Jun 22, 2026, 8:05 AM EDT

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

– Company reports record demand for YCANTH ® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch – – Company announces achievement of over 50% of current targeted

Presentation / Abstract • Phase 2SID late-breaking oral presentation Wed, May 13, 2026

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the

Presentation / Abstract • Phase 2

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking

Presentation / Abstract • Phase 2

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief

Verrica Pharmaceuticals Inc. • Endpoint Arena